Transregional Collaborative Research Centre 152

Breadcrumb Navigation


Curriculum Vitae

Advanced Professional Positions

  • 2016 – present Vice dean for research at Medical Faculty, Leipzig University
  • 2008 – present, Full professor (W3) and head of the Rudolf-Boehm-Institute, Medical Faculty, University of Leipzig
  • 2004 – 2008 Professor (C3) “Pharmacology and Cellular Signal Transduction”, Charité - Universitätsmedizin Berlin
  • 2000 – 2004 Group leader and research assistant (C1), Institute of Pharmacology, Freie Universität Berlin and Charité - Universitätsmedizin Berlin, Advisor: Günter Schultz

Professional Experience and Postdoctoral Training

  • 1995 – 2000 Research fellow and first year resident, Institute of Pharmacology, Freie Universität Berlin, Germany, Advisors: Günter Schultz and Thomas Gudermann

Academic Education

  • 2003 Habilitation (Pharmacology and Toxicology), Freie Universität Berlin, Mentor: Günter Schultz
  • 2002 Specialist in Pharmacology and Toxicology, Facharztanerkennung der Ärztekammer Berlin
  • 1996 Dr. med., Ludwig-Maximilians-Universität München, Mentor: Rupert Gerzer
  • 1994 Medical Degree, Ludwig-Maximilians-Universität München

Honours, Awards, Scholarships and Other Qualifications

  • 2004 Research Award of the Carl-Zeiss-Stiftung
  • 2004 Professorship (C3) offered at the Ruprecht-Karls-Universität Heidelberg
  • 2003 Buchheim Award of the German Pharmacological Society (DGPT)
  • 1999 – 2002 Research Awards (2 first, 1 second) of the Medical Faculty, FU Berlin

Professional Activities, Memberships

  • since 2008 Member of the German Purine Club
  • 2001-2007 Member of the American Society for Biochemistry and Molecular Biology
  • 2000 - present Member of the Deutsche Gesellschaft für experimentelle und klinische Pharmakologie und Toxikologie


  • Urban N, Neuser S, Hentschel A, Köhling S, Rademann J, Schaefer M. Pharmacological inhibition of focal segmental glomerulosclerosis-related, gain of function mutants of TRPC6 channels by semi-synthetic derivatives of larixol. Br J Pharmacol 174:4099-4122, 2017.
  • Beckmann H, Richter J, Hill K, Urban N, Lemoine H, Schaefer M. A benzothiadiazine derivative and methylprednisolone are novel and selective activators of transient receptor potential canonical 5 (TRPC5) channels. Cell Calcium 66:10-18, 2017.
  • Spyra S, Meisner A, Schaefer M, Hill K. COX-2-selective inhibitors celecoxib and deracoxib modulate TRPV3 channels. Br J Pharmacol 174:2696-2705, 2017.
  • Krügel U, Straub I, Beckmann H, Schaefer M. Primidone inhibits TRPM3 and attenuates thermal nociception in vivo. Pain 158:856-867, 2017.
  • Urban N, Wang L, Kwiek S, Rademann J, Kuebler WM, Schaefer M. Identification and validation of larixyl acetate as a potent TRPC6 inhibitor. Mol Pharmacol 89:197-213, 2016.
  • Nörenberg W, Plötz T, Sobottka H, Chubanov V, Mittermeier L, Kalwa H, Aigner A, Schaefer M. TRPM7 is a molecular substrate of ATP-evoked P2X7-like currents in tumor cells. J Gen Physiol 147:467-483, 2016.
  • Chen CC, Keller M, Hess M, Schiffmann R, Urban N, Wolfgardt A, Schaefer M, Bracher F, Biel M, Wahl-Schott C, Grimm C. A small molecule restores function to TRPML1 mutant isoforms responsible for mucolipidosis type IV. Nat Commun 14;5:4681, 2014.
  • Richter JM, Schaefer M, Hill K. Clemizole hydrochloride is a novel and potent inhibitor of transient receptor potential channel TRPC5. Mol Pharmacol 86:514-521, 2014.
  • Schulze A, Hartung P, Schaefer M, Hill K. Transient receptor potential ankyrin 1 (TRPA1) channel activation by the thienopyridine-type drugs ticlopidine, clopidogrel, and prasugrel. Cell Calcium 55:200-207, 2014.
  • Straub I, Mohr F, Stab J, Konrad M, Philipp SE, Oberwinkler J, Schaefer M. Citrus fruit and fabacea secondary metabolites potently and selectively block TRPM3. Br J Pharmacol 168:1835-1850, 2013.